Related Experiment Video
Updated: Jul 23, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Diagnostic Dilemmas in Hepatitis C Virus Infection for Hemodialysis Patients
Radka T Komitova1, Maria V Atanasova2, Toska A Pavlova3
1Department of Infectious Diseases, Parasitology and Tropical Medicine, Faculty of Medicine, Medical University of Plovdiv, 15A Vassil Aprilov Blvd., 4002 Plovdiv, Bulgaria.
Insights
Hepatitis C virus (HCV) infection in dialysis patients is best diagnosed using both serological and biomolecular tests. This dual approach improves accuracy in identifying HCV in this vulnerable population.
Area of Science:
- Nephrology
- Hepatology
- Infectious Diseases
Background:
- Hepatitis C virus (HCV) is a significant cause of chronic hepatitis among patients undergoing dialysis.
- Clinical presentation of HCV in dialysis patients is often non-specific, necessitating reliable laboratory diagnostics.
Purpose of the Study:
- To accurately determine the prevalence of HCV infection in dialysis patients.
- To evaluate the efficacy of simultaneous anti-HCV antibody and HCV RNA testing for diagnosis.
Main Methods:
- Prospective, cross-sectional longitudinal study of 93 dialysis patients over 18 months.
- Simultaneous testing for anti-HCV antibodies (ELISA) and HCV RNA (RT-PCR) in plasma and mononuclear cells.
- Repeated testing for anti-HCV negative patients to ensure accurate diagnosis.
Main Results:
- Overall seroprevalence of HCV was 20.6% in 68 patients.
- 10 patients were viremic (HCV RNA+/anti-HCV+), and 4 (5.9%) showed discordant results (anti-HCV+/HCV RNA-).
- Viremic patients had a significantly longer duration of dialysis (p=0.005).
Conclusions:
- Simultaneous serological and biomolecular testing enhances the accuracy of HCV diagnosis in dialysis patients.
- A combined diagnostic strategy is recommended for improved detection rates.
- Larger studies are needed to validate this approach for national implementation.
Background:
Hepatitis C virus (HCV) is a leading cause of chronic hepatitis in dialysis patients. The diagnosis of HCV infection in these patients is predominantly based on laboratory tests because of the specificity of the clinical course of the disease.
Aim:
The present prospective study aimed at determining very accurately the prevalence rate of HCV infection in patients on dialysis by simultaneously testing them for anti-HCV and for HCV RNA levels.
Materials And Methods:
For the present cross-sectional longitudinal study we recruited and followed up 93 patients from St George University Hospital Hemodialysis Unit between July 2013 and December 2014. All patients were tested for anti-HCV and HCV RNA. The anti-HCV negative patients were tested for anti-HCV and HCV RNA at least twice at intervals of 6 months or more (up to 12 months). Anti-HCV antibodies were identified using a third generation ELISA assay. Commercial kits for real-time polymerase chain reaction (RT-PCR) were used to detect HCV RNA in the plasma and mononuclear cells. Aminotransferase and gammaglutamyl transpeptidase levels were studied to find if liver inflammation was present.
Results:
The total seroprevalence in 68 patients was 20.6% (14). Of these, 10 patients were viremic (HCV RNA+/anti-HCV+), and 4 patients (5.9%) had discordant results (anti-HCV+/HCV RNA-). Acute hepatitis was detected in one patient. Duration of dialysis in HCV viremic patients was longer than that in aviremic patients (p=0.005).
Conclusions:
The present study suggests that HCV infection in dialysis patients can be diagnosed more accurately if these patients are tested using two diagnostic methods - a serological test and a biomolecular assay. Further studies with larger sample size may prove the feasibility of such approach for all dialysis patients in this country.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Hemodialysis I: Introduction
Hemodialysis II: Procedure and Complications
Hemodialysis III: Nursing Management
Hepatitis

